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than 60 (Shulman et al., 2006). With
aging, acquired skewing occurs in
normal females and is present in 38%
of women over the age of 60 years
(Busque et al., 1996), whereas truly
random lyonization is rare (El Kassar
et al., 1998). Whether acquired skew-
ing is a consequence of stem cell
depletion, true clonal tumor expansion,
growth advantage conferred by paren-
tal-specific X-chromosomes, or other
unknown mechanisms has not been
elucidated yet. Unfortunately, the
authors do not address the putative
influence of skewing on the outcome
of their study, although the broad range
of variation conferred by this mecha-
nism might provide a better explanation
for their data. A further disadvantage of
X-chromosome inactivation studies of
tumors is that they are only informative
when interpreted in the context of the
clonal composition of the surrounding
normal tissue and correlated with an
adequate sample number of normal
control tissue from age-matched indivi-
duals (Novelli et al., 2003). We feel that
the latter aspect was also insufficiently
addressed by Shulman et al. because
they did not incorporate age-matched
controls for lyonization. Another im-
portant factor, often ignored in such
studies, is the distribution of X-inacti-
vated cells in tissues. Taking into
consideration that lyonization occurs
early in development, many of the
progeny of a single embryonic stem
cell are grouped together in the adult,
forming patches. As polyclonality can
only be demonstrated at the borders of
X-inactivation patches, not only the
patch size is crucial in determining
the chance of demonstrating polyclon-
ality but also the number of tumors that
need to be examined to exclude poly-
clonality (Novelli et al., 2003) – one
more aspect not considered by the
authors.
In conclusion, we believe that the
authors did not deliver sufficient evi-
dence to support their theory that
anatomically and temporally distinct
BCCs can originate from one single
tumor cell clone.
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TO THE EDITOR
To the comments and concerns raised
by Drs van Steensel and Frank ( Journal
of Investigative Dermatology advance
online publication, 27 July 2006, doi:
10.1038/sj.jid.5700471), regarding the
main conclusion contained in our
manuscript ‘‘Monoclonal origin of ana-
tomically distinct basal cell carcino-
mas’’ (Shulman et al., 2006), we offer
the following responses:
1. It was never claimed anywhere by
us in the manuscript that the clone
precursor cell of anatomically dis-
tinct basal-cell carcinoma (BCC)
represents a metastatic process. If
we use the classical example of
another disorder, namely McCune–
Albright syndrome (OMIM# 174800),
it is clear that in this syndrome,
there is a post-zygotic mutation in
the Gs alpha gene – so-called gsp
mutation – that is contained in all
affected tissues (cafe´ au lait spots
included), and has been acquired
during embryogenesis (Weinstein
et al., 1991). It is evident that the
McCune–Albright syndrome is notAbbreviations: BCC, basal-cell carcinoma; LOH, loss of heterozygosity; PTCH, patched
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a cancerous process, and the ex-
istence of a similar mutation in all
affected tissues is indicative of the
monoclonal and common precur-
sor cell in this disease entity,
rather than a metastatic spread.
Similarly, it is totally plausible that
a similar process that involves a
post-zygotic mutation in a tumor
suppressor gene (patched (PTCH)
gene or other unidentified gene)
could underlie and account for our
data.
2. We are surprised to read Drs van
Steensel and Frank’s comment and
critique that loss of heterozygosity
(LOH) determination and X-chro-
mosome inactivation patterns are
invalid technologies and ap-
proaches to assessing tumor mono-
clonal origin. There are many
articles that have assessed clonality
using the combination of both
techniques and applied for both
benign and malignant tumors
(Arnold et al., 1988; Friedman
et al., 1989). In a quote from a
recent review of the clonal origin of
benign pituitary tumors, Clayton
and Farrell (2004) note, ‘‘Allelo-
type analysis and X-chromosome
inactivation analysis in women
enables the assessment of tissue
clonality’’. Similarly, Diaz-Cano
et al. (2001), who reviewed the
techniques for assessing clonality
state, ‘‘LOH analyses identify clo-
nal expansions of a tumor cell
population, and point to monoclo-
nal proliferation when multiple
and consistent LOH are demon-
strated. Based on the methylation-
related inactivation of one X chro-
mosome in female subjects, X-
linked markers (e.g., androgen re-
ceptor gene) will provide clonality
information using LOH analyses
after DNA digestion with methyla-
tion-sensitive restriction endonu-
cleases’’.
3. We agree that analysis of patients
for PTCH gene mutations would
strengthen the data. However, if
the tumor suppressor gene targeted
by the LOH is an unidentified gene,
even the lack of PTCH gene germ-
line mutations would not preclude
or override our data.
4. We chose the markers to test LOH
by applying the ones that were
successful in previous allelotyping
studies of BCCs (Iwata et al., 2004).
If these markers are outside of the
region containing the PTCH gene,
they might indicate that a tumor
suppressor gene, distinct from
PTCH, that resides within the same
chromosomal region is targeted for
inactivation by the LOH. Hence,
even not finding recurrent somatic
mutations in the distinct tumor
samples would not negate our
findings. We would welcome, in a
collaborative manner and spirit,
any assistance from Drs van Steen-
sel and Frank in sequencing the
tumor samples for PTCH gene
mutations.
5. We are surprised by the comments
regarding the meiotic recombina-
tion and its putative effect on LOH.
The LINE element is present in
the tumor tissue as well as in
germline DNA. As LOH by defini-
tion is a somatic event, why did the
recombination occurred preferen-
tially and exclusively in the tumor
tissue? In addition, we are well
aware of other genes and loci
involved in the pathogenesis of
BCC. We fail to see the relevance
of this information to the LOH data,
or any other aspect of our study.
The most important and crucial
finding in our study is the fact
that in the same patient, anatomi-
cally distinct tumors (as many as
four in one case) always showed
LOH of the same allele. The odds
that this phenomenon represents a
chance occurrence or a mere co-
incidence is statistically negligible,
despite the beliefs echoed in the
comment by Drs van Steensel and
Frank.
6. Random extreme lyonization is
indeed rare. Even though acquired
X-inactivation pattern is more pre-
valent in aging women, it seems
unlikely to explain the data: we
used normal surrounding tissue as
normal control tissue. Acquired
skewed X inactivation does not
preferentially occur in tumor tissue.
Thus, the use of ‘‘adequate sample
of normal surrounding tissue’’ re-
quested by Drs Van Steensel and
Frank is met. In essence, this use
also means that requiring similar
analysis of age-matched controls is
redundant and superfluous.
Furthermore, only one tumor in
the analysis of X-chromosome in-
activation was the determining
factor in evaluating clonality. In
all others, the evaluation and
assignment of clonality was primar-
ily based on LOH and only
supported by X-chromosome inac-
tivation patterns.
7. In conclusion, without invoking
our own beliefs, we employed
time-honored, well-accepted, and
practiced techniques to assess
monoclonal origin of BCC and
provide a plausible, novel insight
into the clonal origin of anatomi-
cally distinct BCC.
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